As of 2025-11-05, the EV/EBITDA ratio of Fate Therapeutics Inc (FATE) is -0.61. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FATE's latest enterprise value is 95.99 mil USD. FATE's TTM EBITDA according to its financial statements is -156.19 mil USD. Dividing these 2 quantities gives us the above FATE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.0x - 15.0x | 13.6x |
| Forward P/E multiples | 11.6x - 16.3x | 13.4x |
| Fair Price | (15.92) - (19.96) | (17.92) |
| Upside | -1437.9% - -1777.0% | -1606.3% |
| Date | EV/EBITDA |
| 2025-11-03 | -0.66 |
| 2025-10-31 | -0.73 |
| 2025-10-30 | -0.69 |
| 2025-10-29 | -0.73 |
| 2025-10-28 | -0.84 |
| 2025-10-27 | -0.88 |
| 2025-10-24 | -0.95 |
| 2025-10-23 | -0.86 |
| 2025-10-22 | -0.84 |
| 2025-10-21 | -0.87 |
| 2025-10-20 | -0.87 |
| 2025-10-17 | -0.82 |
| 2025-10-16 | -0.87 |
| 2025-10-15 | -0.87 |
| 2025-10-14 | -0.84 |
| 2025-10-13 | -0.76 |
| 2025-10-10 | -0.94 |
| 2025-10-09 | -0.92 |
| 2025-10-08 | -0.85 |
| 2025-10-07 | -0.76 |
| 2025-10-06 | -0.78 |
| 2025-10-03 | -0.63 |
| 2025-10-02 | -0.63 |
| 2025-10-01 | -0.66 |
| 2025-09-30 | -0.67 |
| 2025-09-29 | -0.47 |
| 2025-09-26 | -0.47 |
| 2025-09-25 | -0.45 |
| 2025-09-24 | -0.48 |
| 2025-09-23 | -0.45 |
| 2025-09-22 | -0.48 |
| 2025-09-19 | -0.45 |
| 2025-09-18 | -0.47 |
| 2025-09-17 | -0.44 |
| 2025-09-16 | -0.44 |
| 2025-09-15 | -0.44 |
| 2025-09-12 | -0.45 |
| 2025-09-11 | -0.49 |
| 2025-09-10 | -0.47 |
| 2025-09-09 | -0.46 |
| 2025-09-08 | -0.45 |
| 2025-09-05 | -0.48 |
| 2025-09-04 | -0.45 |
| 2025-09-03 | -0.47 |
| 2025-09-02 | -0.50 |
| 2025-08-29 | -0.50 |
| 2025-08-28 | -0.53 |
| 2025-08-27 | -0.56 |
| 2025-08-26 | -0.56 |
| 2025-08-25 | -0.54 |